Skip to content
Biophytis
LIVE HEALTHIER LONGER
Biophytis
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
    • Recruitment
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Macuneos (BIO201)
    • Posters & Publications
  • Pipeline
    • Key milestones in the development of Sarconeos (BIO101)
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
  • News
    • Press Releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
    • Recruitment
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Macuneos (BIO201)
    • Posters & Publications
  • Pipeline
    • Key milestones in the development of Sarconeos (BIO101)
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
  • News
    • Press Releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN

April 04, 2017

Biophytis secures funding for phase 2B clinical trial in Sarcopenia, SARA-INT. Read the Press Release

Partager cet article
Share on LinkedInShare on LinkedIn TweetShare on Twitter Share on FacebookShare on Facebook Pin itShare on Pinterest Share on WhatsAppShare on WhatsApp

Post navigation

PreviousPrevious post:March 27, 2017NextNext post:April 27, 2017
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
    • Recruitment
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
      • 2014
    • Macuneos (BIO201)
    • Posters & Publications
  • Pipeline
    • Key milestones in the development of Sarconeos (BIO101)
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Investors
    • Live Stock Price
    • Corporate Presentation
    • General Meetings
      • 2022
      • 2021
      • 2020
    • AMF Regulated Information
    • SEC Filings
    • Financial Calendar
  • News
    • Press Releases
      • 2022
      • 2021
      • 2020
      • 2019
      • 2018
      • 2017
      • 2016
      • 2015
    • Biophytis in Media
  • Recruitment
  • Contact
    • Contact
    • Contact Information
    • Legal information
  • LinkedIn
  • Twitter
  • FR
  • EN
BIOPHYTIS
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
  • Our Science
    • Sarconeos (BIO101)
    • Posters & Publications
    • Macuneos (BIO201)
    • Posters & Publications
  • Investors
    • Financial Calendar
    • AMF Regulated Information
  • Pipeline
    • Key programs milestones
    • COVID-19: COVA clinical program
    • Sarcopenia: SARA clinical program
    • Duchenne Muscular Dystrophy: MYODA clinical program
    • Age-related Macular Degeneration: MACA clinical program
  • Contact
    • Contact Information
© Biophytis 2006-2022 - Mentions Légales
  • Corporate
    • Executive Committee
    • Scientific Advisory Board
    • Boards of Directors
    • Code of Ethics
Footer Colonne 1 - Anglais
Go to Top